On May 14, 2025, HC Wainwright & Co., a reputable investment research firm, maintained its "Buy" rating for Revolution Medicines (RVMD, Financial). This decision was made by analyst Robert Burns, emphasizing continued confidence in the company's potential and growth prospects.
Despite maintaining its "Buy" rating, HC Wainwright & Co. adjusted its price target for Revolution Medicines (RVMD, Financial), lowering it from $73.00 to $72.00. This adjustment represents a marginal decrease of 1.37%, indicating a slight recalibration of expectations.
The changes in the price target reflect nuanced analyses by the research firm, oriented around Revolution Medicines' current and anticipated market performance. Investors of RVMD are advised to consider this updated price target in their investment strategy, as it aligns with the current market valuation and outlook.
As of the latest update, Revolution Medicines (RVMD, Financial) continues to trade on the NASDAQ exchange, providing investors with opportunities in the biotech sector. The analyst's maintained rating and adjusted price target underscore the potential that HC Wainwright & Co. foresees for RVMD in the coming months.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 10 analysts, the average target price for Revolution Medicines Inc (RVMD, Financial) is $72.70 with a high estimate of $88.00 and a low estimate of $57.00. The average target implies an upside of 83.61% from the current price of $39.60. More detailed estimate data can be found on the Revolution Medicines Inc (RVMD) Forecast page.
Based on the consensus recommendation from 12 brokerage firms, Revolution Medicines Inc's (RVMD, Financial) average brokerage recommendation is currently 1.5, indicating "Buy" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Revolution Medicines Inc (RVMD, Financial) in one year is $0.35, suggesting a downside of 99.12% from the current price of $39.595. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Revolution Medicines Inc (RVMD) Summary page.
